AbCellera provided updates on their pipeline progress and financials, emphasizing their transition to a clinical stage biotech company. They anticipate CTA filings for two programs in Q2 next year. They highlighted their new headquarters and GMP manufacturing facility progress.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing